loading...| Preferred Name |
ocrelizumab |
|
| Synonyms |
RO4964913 |
|
| Definitions |
A Fc-modified, humanized monoclonal antibody directed against the B-cell CD20 cell surface antigen, with immunosuppressive activity. Ocrelizumab binds to CD20 on the surfaces of B-cells, triggering complement-dependent cell lysis (CDCL) and antibody-dependent cell-mediated cytotoxicity (ADCC) of B-cells overexpressing CD20. The CD20 antigen, a non-glycosylated cell surface phosphoprotein that acts as a calcium ion channel, is found on over 90% of B-cells, B-cell lymphomas, and other lymphoid tumor cells of B-cell origin; it plays an important role in B-cell functioning. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C66250" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C66250" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000780147 |
|
| altLabel |
RO4964913 |
|
| CAS Registry |
637334-45-3 |
|
| cui |
C1882138 C4287714 |
|
| DATE FIRST PUBLISHED |
2016-04-11 |
|
| Date last modified |
2016-04-08 |
|
| definition |
A Fc-modified, humanized monoclonal antibody directed against the B-cell CD20 cell surface antigen, with immunosuppressive activity. Ocrelizumab binds to CD20 on the surfaces of B-cells, triggering complement-dependent cell lysis (CDCL) and antibody-dependent cell-mediated cytotoxicity (ADCC) of B-cells overexpressing CD20. The CD20 antigen, a non-glycosylated cell surface phosphoprotein that acts as a calcium ion channel, is found on over 90% of B-cells, B-cell lymphomas, and other lymphoid tumor cells of B-cell origin; it plays an important role in B-cell functioning. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C66250" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C66250" NCI Thesaurus) |
|
| NCI ID |
C66250 |
|
| notation |
CDR0000780147 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
ocrelizumab |
|
| tui |
T116 T129 T121 |